Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Core Viewpoint - Nuvectis Pharma, Inc. has made significant progress in its NXP900 development program during 2025, with multiple potential data readouts expected in 2026, while maintaining a focus on operational execution and financial responsibility [2]. Financial Results - As of December 31, 2025, the company's cash and cash equivalents increased to $31.6 million from $18.5 million in 2024, reflecting a rise of $13.1 million due to a public offering and access to an at-the-market facility, partially offset by operating expenses [3]. - The net loss for the year ended December 31, 2025, was $26.4 million, an increase of $7.4 million compared to a net loss of $19.0 million in 2024. This loss included $6.0 million in non-cash stock-based compensation and one-time license fees of $2.4 million [4]. - Research and development expenses for 2025 were $18.2 million, up from $12.9 million in 2024, marking an increase of $5.3 million. General and administrative expenses rose to $9.4 million from $6.9 million, an increase of $2.5 million [5]. - Finance income for 2025 was $1.1 million, compared to $0.8 million in 2024, reflecting an increase of $0.3 million [6]. Company Overview - Nuvectis Pharma, Inc. is focused on developing innovative precision medicines for serious unmet medical needs in oncology, with its primary asset being NXP900, an oral small molecule inhibitor targeting SRC Family Kinases [7].